The widely used Rankin Scale (1) has three limitations: lack of precise criteria defining each stage, moderate reliability, and low ability to detect disability suggestive of dementia. We produced a study using Rankin Scale with a revised structured interview (2,3) and examined its effect on:
• disability rating • ability to detect impaired Instrumental Activities of Daily Living (IADL) characteristic of dementia, and • reliability.
Our study was performed in 70 patients (mean age: 64 Ϯ 15·5; Sex male: 37/70; infarct: n = 60) at the poststroke follow-up visit (interval: 185 Ϯ 100 days) in Amiens University Hospital and Beauvais General Hospital. Two of five examiners graded the Rankin Scale rated:
• conventionally, • following Barthel Index, and • using the revised structured interview.
Retest was performed in a sub-group of 36 randomized patients by telephone interview (42.8 Ϯ 39 days after the faceto-face assessment). Finally, the rela tionship with impairment of IADL and MiniMental Status Examination (MMSE) (4) was examined.
The disability rating increased after assessment by Barthel Index (P = 0·03) and further increased after structured interview (P = 0·0001). This was because of the increased detection of disability in 18/46 patients initially rated as Rankin 0 (n = 10), 1 (n = 21), or 2 (n = 15). The structured interview accurately detected the 28 patients with impaired 4IADL and the 22 patients with both MMSE and IADL impairment as all of them had a Rankin score Ն3 (sensitivity = 1,both).Conversely,sensitivity was lower (P = 0·001, both) for both other ratings (sensitivity of conventional and post-Barthel ratings: 0·75 and 0·786, respectively). Retest by telephone interview showed overall good to excellent agreement with higher Kappa values using structured interview (conventional procedure: kw = 0·822; post-Barthel rating: kw = 0·844; structured interview: kw = 0·924).
These results indicate that grading of the Rankin Scale based on structured interview provides more sensitive and reliable assessment of poststroke disability and might improve the diagnosis of poststroke dementia.
Plasma biomarker may help to distinguish acute CVST from non-thrombotic CVSS in emergency
Cerebral venous sinus thrombosis (CVST) is one of the important causes of stroke in young people and a lethal event (1) . Acute CVST is overlapped with non-thrombotic cerebral venous sinus stenosis (CVSS) in both clinical presentation and brain imaging (2); both of them are predominantly involved in young women, and have severely non-explained headache with vomiting and the imaging feature of non-integrity venous sinus in magnetic resonance venography (MRV) (2). However, the treatment option and the clinical outcomes are entirely different, CVST is typically treated with anticoagulants, whereas non-thrombotic CVSS is treated with dehydration and stenting (3, 4) . Although CVST can be distinguished from CVSS by digital subtraction angiography (DSA), it is unfeasible in the emergency department (ED). Moreover, thrombolysis should be performed emergently to some intractable and severe CVST. Thus, distinguishing these two diseases in hyperacute stage is crucial. Report showed that d-dimer may helpful in supporting CVST (5) , but the result in CVSS is not clear. We compared the levels of plasma biomarkers (D-dimer and fibrinogen) between 34 cases of acute CVST (symptom onset within seven-days) and 34 synchronal cases of age-and gender-matched nonthrombotic CVSS; all of them are confirmed the final diagnosis with DSA. The results revealed significant difference of the two biomarkers in the two groups; 94·1% (32/34) cases in acute CVST group and 5·9% (2/34) in non-thrombotic CVSS group had abnormally elevated d-dimer; 73·5% (25/34) in acute CVST group and 17·6% (6/34) in non-thrombotic CVSS group had abnormally elevated fibrinogen (c 2 = 52·941 and 18·285, all P < 0·001). More importantly, d-dimer and fibrinogen can easily be performed at real time in ED. The results can be obtained within 30 mins after the patient arrives, which is quicker than obtaining the magnetic resonance imaging or DSA imaging. So, these two biomarkers may be helpful and feasible in ED to predict acute CVST in patients with equivocal clinical symptoms, or to distinguish CVST from CVSS when the imaging of MRI/MRV is equivocal.
Transient ischemic attack: the 'waste basket'
Since 'transient ischemic attack' (TIA) was first described, it has been used as a 'waste basket' for transient non-specific symptoms such as blurred vision, dizziness, pain, generalized weakness, syncope, and alteration of consciousness. Most likely, clinicians who are not neurologists are diagnosing neurological conditions with little experience, or no straightforward definition or clinical score to assist them define and diagnose TIA correctly.
Neurologists who stratify TIA patients based upon the 30-day risk of stroke use the ABCD2 score (1) . Very few studies showed the ABCD2 score as useful in differentiating TIAs vs. non-TIAs, which may be difficult for nonneurologists to attain based on clinical grounds (2) . Although magnetic resonance imaging (MRI) has been useful in establishing the diagnosis of TIA vs. stroke, approximately 50% of patients who present with transient neurological symptoms have a normal MRI (3).
The use of MRI is limited in emergency departments although this is where most patients with transient neurological symptoms present.
It is important to have a clearer definition or validated clinical score for TIA to help non-neurologists make appropriate diagnosis on clinical grounds and differentiate TIA from other nonspecific symptoms. It may be helpful to expand the definition to TIA to describe associated focal deficits such as aphasia, dysarthria, unilateral limb or body weakness or numbness, diplopia, and unilateral vision loss. It might also be useful to state symptoms unlikely to be TIA related such as loss of consciousness, blurred vision, lightheadedness, pain, alteration of consciousness without focal deficit, and generalized weakness. It is important to define a time of onset for symptom duration if the symptom occurs intermittently. This may allow clinicians to stratify patients into three groups (TIA, possible TIA, and non-TIA) based on clinical score, thus identifying patients who really have TIA vs. those who have not.
